DNMT3A and cyclic hematopoiesis: These findings suggest that DCAF8 monitors abnormal DNMT3A for degradation, contributing to disease pathogenesis, and provide a rationale for developing DCAF8 inhibitors as potential treatments for DNMT3A mutation-induced CH.